reSET-O, the first PDT to receive Breakthrough Designation and authorized by FDA in December 2018, is an 84-day Prescription Digital Therapeutic (PDT) for Opioid Use Disorder (OUD) intended to increase retention of patients in outpatient treatment by providing cognitive behavioral therapy (CBT), as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician.

SilverCloud is a highly innovative cloud based platform that enables healthcare organisations to deliver a broad range of engaging therapeutic programs to their clients through a managed, secure and supportive environment.

These programs cover the full spectrum of health and wellness from Depression and Anxiety to Addictions and Long Term Illness.

SilverCloud Health was created out of the Technology Enhanced Therapy project, a joint translational research project undertaken by the NDRC (National Digital Research Center) and Trinity College Dublin’s Computer department and Parents Plus, Mater University Hospital Dublin.

For individuals with substance use disorder (SUD), reSET® is the first FDA-authorized prescription digital therapeutic that’s proven to increase abstinence and treatment retention. Patients download the reSET app to their smartphone for secure, discreet, convenient access to therapy, interactive learning, and support.